A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: Final results

4598 Background: Hepatocellular carcinoma (HCC) express the epidermal growth factor receptor (EGFR), and EGFR-targeting therapies are known to block tumor growth. We tested the activity of cetuxima...